STAT

STAT+: Pharmalittle: Next big hope for Alzheimer’s might not help most Black patients; drugmakers ask Supreme Court to toss terrorism-support ruling

Critics say any positive impact from the Alzheimer's drug Leqembi will not benefit lower-income patients, who tend to be diagnosed too late.
Source: Alex Hogan/STAT

Top of the morning to you, and a fine one it is. Cool breezes and clear blue skies – at least for now – are wafting above the Pharmalot campus, where the official mascots are settling in for a well-deserved snooze. As for us, we are busy with the usual sorts of things. We are quaffing another cup of stimulation – our choice today is gingerbread – are attempting to get organized, a Quixotic notion in our world. Nonetheless, we are giving it a go.

You’re reading a preview, subscribe to read more.

More from STAT

STAT2 min read
STAT+: Pharmalittle: We’re Reading About Amylyx Pulling Its ALS Drug, GLP-1 Drugs For Parkinson’s, And More
Amylyx Pharmaceuticals will take its ALS drug Relyvrio off the market in the U.S. and Canada, ending a multi-year saga for patients with the rare neurodegenerative disease.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About An OptumRx Contract, 340B Dispute Resolution, And More
Cardinal Health announced its pharmaceutical distribution contracts with UnitedHealth's OptumRx unit will not be renewed after they expire in June.
STAT1 min read
USDA Faulted For Disclosing Scant Information About Outbreaks Of H5N1 Avian Flu In Cattle
With 28 herds in eight states infected with H5N1 bird flu, scientists are calling on the U.S. to release more data to help them assess the risk.

Related Books & Audiobooks